aim
studi
evalu
perform
diasorin
molecular
pjcmv
multiplex
realtim
pcr
pjcmv
pcr
assay
diasorin
molecular
llc
usa
bronchoalveolar
lavag
bal
sampl
compar
direct
immunofluoresc
assay
ifa
detect
pneumocysti
jirovecii
assess
cmv
p
jirovecii
coinfect
rate
immunosuppress
patient
suspect
pneumonia
total
bal
sampl
immunosuppress
patient
submit
pjpifa
test
surplu
sampl
save
test
use
pjcmv
pcr
assay
among
sampl
p
jirovecii
detect
specimen
use
ifa
pjcmv
pcr
respect
eleven
pjcmv
pcr
posit
sampl
neg
direct
ifa
p
jirovecii
sampl
posit
direct
ifa
also
posit
pjcmv
pcr
use
direct
ifa
gold
standard
pjcmv
pcr
sensit
specif
posit
predict
valu
neg
predict
valu
detect
p
jirovecii
respect
howev
review
clinic
diagnosi
specif
ppv
increas
p
jirovecii
sampl
posit
pjcmv
pcr
also
posit
cmv
pjcmv
pcr
coinfect
rate
found
hiv
infect
nonhiv
infect
patient
studi
indic
diasorin
molecular
pjcmv
multiplex
realtim
pcr
assay
higher
sensit
direct
ifa
detect
p
jirovecii
provid
rapid
detect
pj
cmv
infect
bal
sampl
c
elsevi
masson
sa
right
reserv
clinic
suspicion
pjp
test
p
jirovecii
direct
ifa
use
monofluo
p
jirovecii
ifa
test
kit
monofluo
tm
biorad
laboratori
usa
accord
manufactur
instruct
accord
clinic
data
review
patient
evalu
consid
immunosuppress
bal
sampl
submit
test
patient
met
clinic
radiograph
criteria
possibl
pjp
infect
rule
nonhiv
infect
patient
includ
patient
hemato
data
collect
analysi
perform
liaison
mdx
studio
softwar
follow
cycl
condit
use
cycl
follow
cycl
ramp
speed
ramp
speed
captur
mode
test
time
pjcmv
pcr
assay
sampl
process
final
result
approxim
minut
extract
amplif
control
use
detect
pcr
failur
andor
inhibit
posit
neg
control
sampl
includ
run
cmv
pj
posit
molecular
control
purchas
exact
diagnost
exact
diagnost
fort
worth
tx
standard
procedur
use
obtain
analyt
sensit
test
detect
p
jirovecii
cmv
briefli
commerci
avail
control
cmv
ad
buffalo
ny
p
jirovecii
diagnost
fort
worth
tx
chosen
limit
detect
lod
determin
serial
dilut
prepar
pool
bal
neg
matrix
rang
copiesml
copiesml
cmv
copiesml
copiesml
p
jirovecii
lod
defin
minimum
concentr
detect
rate
least
probit
analys
analyt
specif
assess
manufactur
test
panel
lod
determin
ae
copiesml
copi
rxn
cmv
ae
copiesml
copiesrxn
p
jiroveci
current
studi
assay
yield
neg
result
panel
microorgan
target
organ
thu
crossreact
demonstr
result
clinic
sampl
show
p
jirovecii
detect
specimen
use
ifa
pjcmv
pcr
respect
compar
result
obtain
hivinfect
nonhiv
infect
patient
hiv
infect
nonhiv
infect
patient
posit
p
jirovecii
pjcmv
pcr
eleven
sampl
posit
pjcmv
pcr
neg
ifa
sampl
posit
ifa
also
posit
pcr
sampl
neg
pjcmv
pcr
posit
ifa
ct
detect
pj
number
cycl
need
posit
result
obtain
pjcmv
pcr
higher
cycl
sampl
higher
sampl
neg
ifa
suggest
pj
organ
load
lower
pjcmv
pcr
posit
ifa
neg
sampl
use
ifa
gold
standard
pjcmv
pcr
sensit
specif
posit
predict
valu
neg
predict
valu
p
jirovecii
respect
tabl
p
jirovecii
posit
sampl
also
posit
cmv
pjcmv
pcr
coinfect
rate
found
hiv
infect
nonhiv
infect
patient
immunosuppress
condit
respect
sever
method
detect
p
jirovecii
respiratori
clinic
sampl
includ
cytolog
examin
ifa
direct
ifa
test
wide
use
still
first
line
pjp
diagnost
associ
pathogen
dna
detect
test
detect
cystic
trophic
form
p
jirovecii
although
direct
ifa
test
rapid
perform
easier
interpret
cytochem
stain
might
falseneg
result
especi
specimen
nonhiv
infect
patient
sinc
tend
fewer
organ
present
specimen
test
also
depend
upon
skill
experi
observ
term
familiar
differ
morpholog
organ
overal
sensit
specif
direct
ifa
test
demonstr
metaanalysi
articl
evalu
seven
prospect
studi
molecular
techniqu
realtim
pcr
use
diagnost
evalu
pjp
better
sensit
tradit
cytolog
stain
ifa
present
studi
evalu
perform
pjcmv
pcr
assay
store
bal
sampl
ifa
diagnosi
pjp
knowledg
first
evalu
pjcmv
pcr
assay
use
reagent
diasorin
molecular
pjcmv
pcr
show
higher
sensit
specif
diagnos
pjp
hivinfect
nonhiv
infect
immunocompromis
patient
compar
direct
ifa
test
higher
sensit
observ
studi
consist
result
previou
studi
detect
p
jirovecii
bivari
metaanalysi
studi
lu
et
al
present
diagnost
accuraci
p
jirovecii
pcr
techniqu
sensit
rang
specif
rang
anoth
review
report
sensit
rang
specif
rang
pjp
diagnosi
use
pcr
assay
bivari
metaanalysi
system
review
tabl
comparison
p
jirovecii
direct
immunofluoresc
ifa
pjcmv
multiplex
realtim
pcr
assay
result
n
neg
total
previou
studi
compar
perform
realtim
pcr
ifa
also
report
small
number
sampl
posit
realtim
pcr
neg
ifa
test
due
higher
sensit
pcr
studi
eleven
sampl
found
posit
pcr
neg
ifa
potenti
fals
posit
result
compar
ifa
clinic
proven
pjp
clinic
symptom
specimen
overal
higher
cycl
threshold
valu
compar
sampl
posit
method
becam
posit
less
cycl
specif
increas
ppv
increas
eleven
result
consid
trueposit
accord
patient
clinic
diagnost
criteria
one
advantag
pjcmv
pcr
assay
design
close
system
reduc
potenti
carryov
contamin
runtorun
amplicon
caus
falseposit
result
clinic
sampl
open
simultan
step
process
pjcmv
pcr
assay
also
use
respiratori
fluid
like
sputum
bronchial
fluid
cmv
infect
immunomodulatori
action
aggrav
state
immunosuppress
might
lead
higher
risk
opportunist
infect
pathogen
pj
significantli
influenc
outcom
pjp
infect
howev
studi
report
signific
effect
cmv
coinfect
outcom
pjp
although
clinic
signific
concomit
cmv
infect
pjp
poorli
understood
investig
advis
cmv
monitor
close
pjp
infect
patient
pjcmv
pcr
assay
detect
pathogen
singl
sampl
elimin
need
separ
assay
cmv
pcr
test
respiratori
specimen
previou
studi
report
pjp
patient
also
exhibit
coinfect
cmv
percentag
cmv
coinfect
studi
found
patient
consist
previou
studi
signific
differ
hiv
infect
nonhiv
infect
patient
term
cmv
coinfect
limit
studi
initi
studi
question
restrict
scope
studi
data
access
particular
compar
pjcmv
pcr
assay
direct
ifa
test
routin
use
laboratori
anoth
molecular
test
quantit
test
could
provid
specif
organ
load
addit
although
sampl
analyz
patient
meet
clinic
criteria
pjp
clinic
data
patient
summari
find
demonstr
pjcmv
multiplex
realtim
pcr
assay
show
higher
sensit
compar
direct
ifa
detect
p
jirovecii
bal
sampl
might
easili
adapt
use
clinic
microbiolog
laboratori
allow
simultan
detect
pj
cmv
singl
sampl
author
declar
compet
interest
